| Name | Title | Contact Details |
|---|
Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.
Accugenix offers a fixed pricing structure based upon turnaround time requirements. Whether your isolates are routine or require immediate attention, we have the operational flexibility and capacity to meet your needs. We also offer volume pricing
Produits Chimiques Delmar Inc is a Lasalle, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Behavioral Health Professionals, Inc. we take pride in offering expert behavioral health management services. It’s all we do.
Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)